The AudioNotch Tinnitus Treatment Blog

AM101, a drug for treating the acute development of tinnitus, is entering Phase 3 clinical trials. 

Auris Medical today announced enrollment of the first patient into the TACTT21 clinical trial. This phase 3 trial will evaluate the efficacy, safety and tolerability of intratympanic injections of AM-101 in the treatment of acute peripheral tinnitus following traumatic cochlear injury or otitis media. TACTT2 will enroll 330 patients at more than 60 sites primarily in the United States and Canada.

The initiation of the TACTT2 trial follows shortly after the start of TACTT3, its European counterpart. Both have been … Continue Reading

AM 101 is a drug currently in clinical trials for the treatment of tinnitus. A press release explains how it functions:
AM-101 is a small molecule N-methyl-D-aspartate (NMDA) receptor antagonist formulated in a biocompatible gel for intratympanic injection. Emerging evidence suggests that NMDA receptors in the cochlea play a major role in the occurrence of tinnitus following inner ear excitotoxicity, which is characterized by excessive synaptic release of glutamate, the principal neurotransmitter in the auditory system. Cochlear excitotoxicity may be triggered by, for example, trauma (e.g. exposure to excessive noise), neuroinflammation, disturbances in inner ear blood … Continue Reading

Some of you may be aware of a new drug in development for the treatment of acute tinnitus acquired due to noise trauma. Noise trauma actually kills inner ear hair cells not via direct physical trauma, but via excitotoxicity from an increase in glutamate neurotransmitters. The AM-101 drug is designed to specifically counteract this process. Results of experiments thus far have provoked qualified interest. I’m paraphrasing here, but the idea seems to be preventing the “centralization” of the recurrent neural feedback loops that are theorized to result in chronic tinnitus by restoring the peripheral input to the … Continue Reading